

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/590,001	
			Filing Date	8/17/06	
			First Named Inventor	Norman NASH	
			Art Unit	1626	
			Examiner Name	Rebecca L. Anderson	
Sheet	1	Of	3	Attorney Docket Number	33998-705.831

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US-5,955,281	09-21-1999	Brann	
	2.	US-5,912,132	06-15-1999	Brann	
	3.	US-5,707,798	01-13-1008	Brann	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² - Number - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	4.	WO-2005-024057 A1	03-17-2005	Galapagos Genomics N.V.		
	5.	WO-2004-027427 A1	04-01-2004	Astrazeneca AB		
	6.	WO-2003-106683 A1	12-24-2003	Takeda Chemical Industries, Ltd.		✓
	7.	WO-2003-074069 A2 + A3	09-12-2003	Bayer Healthcare AG		
	8.	WO-2001-57074 A1	08-09-2001	Government of the United States of America		
	9.	WO-2000-31261 A2 + A3	06-02-2000	Cadus Pharmaceutical Corporation		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of the form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/590,001
				Filing Date	8/17/06
				First Named Inventor	Norman NASH
				Art Unit	1626
				Examiner Name	Rebecca L. Anderson
Sheet	2	Of	3	Attorney Docket Number	33998-705.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	†6
	10.	CUI, Y. et al., "Potential role of the formyl peptide receptor-like 1 (FPRL1) in inflammatory aspects of Alzheimer's disease," J. Leukocyte Biol. 72(4):628-635 (2002)	
	11.	DENG, X. et al., "A synthetic peptide derived from human immunodeficiency virus type 1 gp120 downregulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the 7-transmembrane G-protein-coupled receptor FPRL1/LXA4R?," Blood 94(4):1165-1173 (1999)	
	12.	GEWIRTZ, A.T. et al., "Mechanisms of active intestinal inflammation and potential down-regulation via lipoxins," Advances in Experimental Medicine and Biol. 507:229-236 (2002) (Abstract)	
	13.	GRONERT, K. et al., "Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release," J. Exp. Med. 187(8):1285-1294 (1998)	
	14.	KLEIN, C. et al., "Identification of surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeast," Nature Biotech. 16(13):1334-1337 (1998)	
	15.	LE, Y. et al., "Formyl-peptide receptors revisited," Trends in Immunol. 23(11):541-548 (2002)	
	16.	LE, Y. et al., "Receptors for chemotactic formyl peptides as pharmacological targets,"	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Includes copy of this form with next communication to applicant. †Applicant's unique citation designation number (optional). ‡See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. †Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). †For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. †Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. †Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 C.F.R. 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 C.F.R. 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/590,001
				Filing Date	8/17/06
				First Named Inventor	Norman NASH
				Art Unit	1626
				Examiner Name	Rebecca L. Anderson
Sheet	3	Of	3	Attorney Docket Number	33998-705.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
		Intl. Immunopharma. 2(1):1-13 (2002)	
	17.	LE, Y. et al., "Pleiotropic roles of formyl peptide receptors," Cytokine and Growth Factor Reviews 12 (1):91-105 (2001)	
	18.	LE, Y. et al., "The neurotoxic prion peptide fragment PrP(106-126) is a chemotactic agonist for the G protein-coupled receptor formyl peptide receptor-like 1," J. Immunol. 166(3):1448-1451 (2001)	
	19.	MADERNA, P. et al., "Influence of lipoxin A4 and other lipoxygenase-derived eicoanoids on tissue factor expression," Am. J. Physiology 279(4):C945-C953 (2000)	
	20.	MURPHY, P.M. et al., "A structural homologue of the N formyl peptide receptor characterization and chromosome mapping of a peptide chemoattractant receptor family," J. Biol. Chem. 267(11):7637-7643 (1992)	
	21.	SERHAN, C.N., "Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: an update and role in anti-inflammation and pro-resolution," Prostaglandins 68-69:433-455 (2002)	
	22.	YAZAWA, H. et al., "Beta myloid peptide (Abeta42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages," FASEB Journal 15(13):2454-2462 (2001)	
	23.	WO05/047899 Search Report dated 2/15/06	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinda Codes of USPTO Patent Documents at www.uspto.gov/MPER/901/04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.